Six big R&D questions for Pfizer as science chief Dolsten exits

The planned exit of longstanding Pfizer Chief Scientific Officer Mikael Dolsten comes at a pivotal moment for the huge drugmaker. The Covid-19 vaccine aura has fully worn off, it’s made a spate of deals to reload its pipeline, and a handful of top executives have been replaced.

It’s likely to take until next year for Pfizer to have a replacement as it mounts an external search. But when they arrive, they’ll face a handful of important issues that are likely to determine the future of the company’s R&D efforts and products.

1. How can Pfizer shore up its obesity pipeline? 

It’s the question that really every pharma outside of Lilly and Novo Nordisk is asking. But it’s arguably most important for Pfizer, which has three weight loss agents in Phase 1 studies. That includes a trial testing its lead candidate, danuglipron, as a once-daily drug after a…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks